The therapeutic approach is considered relevant for managing inflammatory eye conditions where microbial contamination is present or suspected and is applied across domains where additional symptomatic support is needed.

---

Main Uses and Symptom Relief

This combination is commonly used in conditions characterized by periods of heightened symptoms such as acute purulent conjunctivitis, severe forms of keratitis, anterior uveitis, and following intraocular surgery or eye-ball injuries. It helps address symptom clusters related to inflammatory or irritative states and discharge, providing support that helps ease the overall symptom burden. It is applied in scenarios where additional management of symptoms related to physical discomfort is required, assisting with maintaining functional stability during challenging episodes.

“The medication helps address symptoms that create noticeable functional strain, supporting patient comfort during periods of intense ocular distress.”

---

Symptom Support Summary

The solution is considered relevant for use in conditions where symptoms may intensify temporarily, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations and contributes to improved comfort during periods of heightened symptoms.

Eligibility Map: Who can and cannot use Dexachlor — Official Regulatory Information

The following statements outline the official population eligibility and non-eligibility rules for Dexachlor (Chloramphenicol/Dexamethasone Ophthalmic Solution), based strictly on government regulatory documents.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and children aged two years and older are generally eligible under standard labeled conditions.
Populations for whom use is contraindicated	Use is strictly prohibited for patients with known hypersensitivity to any component, a personal or family history of blood dyscrasias (such as aplastic anaemia), or myelosuppression from previous Chloramphenicol exposure.
Eligibility-related restrictions	The medicine must not be used in the presence of active viral diseases (e.g., epithelial herpes simplex keratitis), fungal diseases, or mycobacterial infections of the eye. Use in patients with glaucoma or corneal/scleral thinning requires great caution.
Age-related eligibility rules	Use is contraindicated in neonates (infants less than 28 days old). Use in children under two years is generally not recommended in many regions.
Pregnancy and lactation eligibility status	Use is not recommended during pregnancy or breastfeeding due to potential risks to the infant, including bone marrow toxicity.
Condition-specific eligibility rules	Caution is specified for patients with impaired hepatic or renal function.

---

Connection to the overall eligibility profile Official regulatory documents strictly define who can and cannot use the medicine by establishing three boundaries: contraindication based on allergy, hematological history, and concurrent infection type; non-recommendation for vulnerable groups like infants and pregnant/lactating individuals; and cautionary use for those with pre-existing conditions. This structure dictates who may use the medicine without providing clinical advice.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for the Chloramphenicol/Dexamethasone ophthalmic solution, based strictly on government regulatory labeling.

---

The regulatory documentation identifies several interaction constraints, focusing on both topical administration rules and potential systemic effects of the active ingredients.

Documented Pharmacodynamic and Antagonistic Interactions

Co-administration with Topical Bactericidal Antibiotics (including agents such as Gentamicin and Polymyxin B) is prohibited as these agents may inhibit the bacteriostatic effect of Chloramphenicol. A pharmacodynamic interaction exists with Anticholinergics (e.g., Atropine), as co-use with the corticosteroid component may increase the risk of elevated intraocular pressure in predisposed individuals.

Pharmacokinetic and Exposure-Altering Agents

Agents that induce hepatic enzymes, such as Phenytoin and Rifampicin, are documented to increase the metabolism and clearance of the Dexamethasone component, which can consequently reduce its efficacy. Conversely, the Chloramphenicol component may increase the effect of systemic Anticoagulants, like Warfarin, if significant systemic absorption occurs.

Administration and Population Constraints

If the ophthalmic solution is co-administered with other topical eye products, they must be separated by a minimum of 5 minutes, with any ointments administered last, to prevent product dilution. The product's use is contraindicated in neonates and long-term use is restricted in children, noting the potential for systemic adverse effects. Patients with diabetes mellitus are noted in labeling as having a potentially increased risk of specific ocular complications.

The drug’s activity is achieved through the functional complementarity of its two active ingredients, which execute distinct mechanisms to simultaneously modulate microbial proliferation and the resulting host inflammatory response.

Targeting Microbial Protein Synthesis

Chloramphenicol acts as a bacteriostatic agent by directly targeting the bacterial 50S ribosomal subunit. By binding reversibly to the peptidyl transferase center, it physically blocks the elongation of protein chains, thereby arresting microbial growth. This specific inhibition of bacterial protein synthesis functionally limits the microbial load.

Widespread Anti-Inflammatory Genomic Modulation

Dexamethasone exerts its effect by binding as a high-affinity agonist to the cytosolic Glucocorticoid Receptor (GR). This binding initiates a genomic cascade that results in the transrepression of pro-inflammatory transcription factors, such as NF-kappaB. The physiological consequence is a comprehensive modulation of the host inflammatory pathway, resulting in reduced localized fluid extravasation, decreased vascular permeability, and suppressed leukocyte migration.

Mechanistic Synergy and Dual Control

This fixed combination is characterized by complementary dual action: the antibiotic mechanism addresses the initial cause (microbial proliferation), while the steroid mechanism manages the acute host reaction (inflammation). This functional synergy of bacteriostasis and inflammation suppression determines the drug's comprehensive physiological effect profile.

Dexachlor is a combination medicine, typically administered as an ophthalmic solution (eye drops) to be applied directly to the eye, or is referenced based on the official guidelines for its corticosteroid component, dexamethasone. Dosage and administration rules are highly variable and must be strictly determined by a healthcare provider.

Official Administration Guidelines (Dexamethasone Component)

Administration Scope	General Instructions
Route & Form	Oral: Tablets or liquid solution. Ophthalmic: Solution (as Dexachlor) or ointment. Parenteral: Intravenous (IV) or Intramuscular (IM).
Dosing	Dose is individualized based on condition severity. The general initial oral dosage ranges from 0.5 mg to 10 mg per day. Pediatric doses are lower, based on height and weight, and must be prescribed by a doctor.
Timing & Food	Oral: Take with or immediately after food or milk to minimize gastrointestinal irritation; do not take on an empty stomach. If taken once daily, administer in the morning, often with breakfast, to coincide with the body's natural cortisol rhythm.
Preparation	Oral Liquid: Measure the dose using the provided calibrated oral syringe or measuring spoon; avoid household teaspoons for accuracy. IV: Dexamethasone Sodium Phosphate solution may be diluted with 5% Dextrose or 0.9% Sodium Chloride for IV infusion.
Missed Dose	If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Never take a double dose to compensate for the forgotten one.
Procedural Steps	For continuous or long-term therapy (e.g., more than a few weeks), the dosage must be gradually decreased before discontinuation to prevent withdrawal symptoms or adrenal suppression. Do not stop treatment suddenly without a doctor's instruction.

Research Evidence / Overview of Studies for Dexachlor

---

Evidence for Use in Acute Ocular Inflammation and Suspected Infection

Research exploring the use of the Chloramphenicol/Dexamethasone combination was studied for use in conditions involving inflammation in the anterior eye segment where bacterial involvement is suspected, such as severe cases of conjunctivitis or keratitis. The evidence base includes Randomized Controlled Trials (RCTs) and supporting data contained in Regulatory Assessment Documents. These studies were used in research exploring how symptoms change over time when this dual-action strategy is applied.

The research examined outcomes related to physical discomfort and visual signs of inflammation. Studies monitored changes in symptoms like ocular discharge, eye redness (hyperemia), and localized irritation. Research describes that the observation periods in these trials were typically short-term, usually lasting only 5 to 15 days, and long-term effects are not fully established.

Studies and Outcomes Evaluated

The studies monitored specific markers of inflammatory or irritative states. Researchers tracked how symptoms evolved in the observed populations using objective measurements and clinical rating scales. These outcomes reflecting daily functioning or activity level and the intensity of the physical discomfort were important measures in the trials.

---

Evidence for Use in Post-Surgical Ocular Management

The combination product was studied for the evaluation of inflammation and infection patterns in the immediate period following intraocular procedures, such as cataract surgery. This research primarily involved short-term Randomized Controlled Trials (RCTs) designed to compare the Dexachlor combination against other anti-inflammatory and antibiotic regimens used in the post-operative period.

Research examined temporary physiological imbalance following surgery. Findings describe patterns observed in the studies, including changes in postoperative inflammatory markers (like anterior chamber cells and flare) over defined time intervals. Reported outcomes were assessed within a short follow-up phase, typically up to 15 days post-surgery.

---

Evidence in Special Populations and Research Uncertainty

The clinical evidence for this combination focuses overwhelmingly on Adults. Currently, data are still emerging regarding the appropriate use of the combination product in infants and the paediatric population. Regulatory assessments have noted the limited controlled trial data available for these younger patient groups.

Furthermore, the evidence base has several acknowledged gaps. Comparative evidence is lacking for certain scenarios, as many trials compare the fixed-dose combination against other combination products rather than against the single antibiotic or the single steroid alone.

Key Studies & References

1. Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years - GOV.UK Drug Safety Update

Common questions about Dexachlor (FAQ)

Q: What is the difference between Dexachlor and other similar medicines?

A: According to official product information, Dexachlor is classified as a fixed-dose combination product. This means it contains two distinct active ingredients: the antibiotic chloramphenicol and the corticosteroid dexamethasone. This dual-action strategy is designed to manage both inflammation and bacterial involvement concurrently.

Q: Why do official documents mention the possibility of liver issues with Dexachlor?

A: Official labeling advises caution for patients who have impaired hepatic (liver) or renal (kidney) function. Regulatory caution is issued because impaired liver or kidney function may affect how the drug's components are cleared.

Q: Are there different strengths or forms of Dexachlor available?

A: Regulatory information defines Dexachlor as a sterile ophthalmic solution, or eye drops. The product is specifically formulated to contain fixed concentrations of the two active ingredients, chloramphenicol and dexamethasone. No other dosage forms, such as oral tablets, are defined under the name Dexachlor in these documents.

Q: Is it normal to experience mild stomach upset when taking Dexachlor?

A: Official safety information for the eye drop solution primarily documents effects localized to the eye. However, the corticosteroid component, dexamethasone, when administered systemically, has been linked to potential gastrointestinal irritation or stomach upset. This information is noted for general awareness based on the component's established systemic safety profile.

Q: How does Dexachlor compare to placebo in clinical trials?

A: Regulatory summaries indicate that clinical research has primarily examined Dexachlor in comparison to other combination products or single-agent therapies. Regulatory summaries focus on the benefit of using this dual-action strategy in conditions where both inflammation and infection risk are present.

Q: What does the drug's safety classification (e.g., Pregnancy Category) mean?

A: Drug safety classifications are used in regulatory documents to categorize potential risks associated with use during pregnancy. For example, the former U.S. system used categories like C, which indicated that animal studies showed a risk to the fetus, but that human data was either lacking or insufficient to draw a definitive conclusion. This classification helps describe the available data on potential risk; it is not a substitution for individual medical counseling.

Q: How is Dexachlor eliminated from the body?

A: Official documents indicate that the active components of the drug are processed primarily by the liver (hepatic metabolism). The chloramphenicol component, for example, is metabolized this way, and its clearance rate can be influenced by the health of both the liver and the kidneys.

Q: Do studies suggest Dexachlor is more effective in certain patient groups?

A: Clinical research evidence cited in regulatory documents overwhelmingly focuses on the adult population. While safety and effectiveness have been evaluated for this group, regulatory notes highlight that controlled trial data for younger pediatric patients may be limited.

Q: What is the typical duration of treatment with Dexachlor?

A: Dosage guidelines typically specify short-term treatment courses for acute conditions. Official regimens, such as those for bacterial conjunctivitis, are often described as lasting 7 to 14 days. The specific duration of treatment is determined by a healthcare provider.

Q: Is Dexachlor a controlled substance in the US?

A: Based on regulatory records in the U.S., the combination product Dexachlor is not designated as a controlled substance. The active ingredients, chloramphenicol and dexamethasone, are also not categorized under the federal controlled substance schedules.

Q: Does Dexachlor affect blood pressure?

A: The corticosteroid component, dexamethasone, has been associated with effects on blood pressure, primarily when used systemically or for extended periods. Official documents include cautionary statements for patients with pre-existing hypertension (high blood pressure).

Q: Is it common to feel a little tired when first starting Dexachlor?

A: While the most common reported side effects for the eye drops are localized to the eye, systemic use of the component dexamethasone has been linked to tiredness or fatigue. This possibility is noted in regulatory documents for the purpose of general awareness of the active ingredient's broader profile.

Q: Can Dexachlor cause changes in mood or sleep patterns?

A: Side effect profiles for the corticosteroid component, particularly in systemic formulations, have noted the potential for mental or mood changes. These have included reports of agitation, mood swings, or depression. Official documents also mention trouble sleeping as a possibility related to the active ingredients.

Q: Does Dexachlor interact with common over-the-counter pain relievers?

A: Regulatory warnings include cautionary statements regarding the co-administration of the corticosteroid component with certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This is due to potential interaction risks related to gastrointestinal issues. However, Acetaminophen (Paracetamol) is generally described in relation to the component Dexamethasone as having no known interaction.

Q: Is Dexachlor considered safe for people over 65?

A: Official labeling for the active component dexamethasone includes statements on use in the geriatric (over 65) population. Regulatory documents indicate that no overall differences in effectiveness or safety have been observed between elderly and younger patients in studies of the systemic form.

Q: Does Dexachlor have an official 'Black Box Warning' from the FDA?

A: The official safety profile highlights a critical warning regarding the rare but potentially fatal risk of Aplastic Anaemia associated with the chloramphenicol component. This severity mandates inclusion in official safety documentation for all dosage forms. The specific designation of a 'Black Box Warning' can vary by regulatory document and region.

Q: What ingredients are in the Dexachlor tablet besides the active drug?

A: Regulatory information for the ophthalmic solution lists the active drugs along with several inactive ingredients (excipients). These typically include a preservative, such as phenylmercury nitrate, and other components like sodium bisulfite, which are required for the stability and structure of the eye drop formulation.

Q: Can people with a history of heart conditions use Dexachlor?

A: Regulatory documents contain cautionary statements regarding the systemic use of corticosteroids in patients with pre-existing heart conditions, such as congestive heart failure. This is due to the component's potential to cause fluid retention and blood pressure elevation. Specific cautionary use for ocular application is related to the possibility of systemic absorption.

Q: What kind of specialist usually prescribes Dexachlor?

A: Official indications state that the product is intended for use in inflammatory conditions of the eye where bacterial involvement is suspected. This therapeutic use is within the scope of practice for specialists who treat acute ocular conditions, such as ophthalmologists or optometrists.

Q: Are there known interactions between Dexachlor and herbal supplements?

A: Authoritative medical bodies generally state that data on potential interactions between herbal remedies, supplements, and prescription medicines are often insufficient. Herbal products are not tested for interactions in the same way as regulated prescription drugs, which limits the available regulatory guidance on co-administration.

Q: Can Dexachlor affect fertility?

A: Regulatory bodies note that long-term animal studies to evaluate fertility effects have not typically been performed for the ophthalmic component. However, official information regarding the chloramphenicol component indicates there is no current evidence to suggest it reduces fertility in men or women.

Q: What are the restrictions on driving or operating machinery while on Dexachlor?

A: Regulatory guidance for the use of eye drops often includes a caution regarding temporary blurred vision immediately after instillation. Official guidance notes that due to the potential for temporary blurred vision, activities requiring clear sight, such as driving, should be avoided until vision returns to normal.

Q: Is Dexachlor known to cause weight gain or loss?

A: The systemic use of the corticosteroid component, dexamethasone, has been associated with side effects including weight gain. This information is generally provided to patients using the oral or injectable forms. The side effect profile for the topical eye solution is typically focused on local reactions.

Q: Is a follow-up appointment necessary after starting Dexachlor?

A: Regulatory documents stress the importance of monitoring for potential complications associated with the corticosteroid component, particularly if treatment exceeds 10 days. Regular eye exams and monitoring of intraocular pressure (IOP) may be indicated if the product is used for an extended period.

Q: What is the half-life of Dexachlor (clarification of concept)?

A: Pharmacokinetic data on the active ingredients are available in regulatory documentation. For example, the half-life (the time it takes for half the drug to be eliminated from the body) of the chloramphenicol component in adults with normal renal and hepatic function is typically reported to be between 1.5 and 3.5 hours.

Q: Does Dexachlor have a known interaction with alcohol?

A: Official safety information for the chloramphenicol component indicates that alcohol consumption is generally considered acceptable while using the drops.

Q: Is it possible to develop a tolerance to Dexachlor over time?

A: Research has examined the concept of acute tolerance, also known as tachyphylaxis, which is associated with topically applied corticosteroids. This suggests the possibility of a decreased therapeutic response over time with continuous or prolonged treatment.

Q: Can Dexachlor interact with common birth control pills?

A: Regulatory information states that the chloramphenicol component may potentially reduce the effectiveness of hormonal birth control containing estrogen. This potential interaction is noted due to the possibility of increased pregnancy risk.

Q: Can Dexachlor be crushed or broken if I have trouble swallowing pills?

A: According to official documents, Dexachlor is designated as a sterile ophthalmic solution (eye drops), intended for topical use on the eye only. This dosage form is not a pill or capsule and should never be swallowed, crushed, or broken.

How to Store and Dispose of Dexachlor Ophthalmic Solution

Official regulatory documents mandate strict conditions to maintain the sterility and stability of Dexachlor, an ophthalmic solution.

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C or not above 25 C, depending on the formulation.
Protection	The medicine must be protected from light and kept in its original package.
Prohibited	Do not freeze the solution, and avoid refrigeration for some formulations.
Child Safety	Keep out of the reach of children.

Stability and Disposal

Once the container is first opened, the solution has a limited in-use stability period of 28 days, after which any remaining product must be discarded to prevent contamination. Any unused or expired Dexachlor must not be disposed of via wastewater or household trash. Disposal must be performed in accordance with local pharmaceutical waste regulations.